Almirall S.A. and LEO Pharma A/S announced today a unique collaboration that aims to advance understanding of skin diseases by setting a new standard for skin sampling.
The companies aim to develop and clinically validate a painless, minimally invasive skin sampling method that enables accurate and comprehensive biomarker analysis in clinical trials and exploratory research.
The agreement is unique in that it is the first time leading dermatology players join forces in research to advance understanding and treatment of skin diseases.
Eduardo Sanchiz, CEO of Almirall commented: “We are very pleased with this collaboration with LEO Pharma, which will provide the scientific community with new tools to understand and treat skin diseases. This project is another step in gaining a deeper understanding of these pathologies so that, in the future, we will be able to provide solutions to cover healthcare professionals and patients unmet needs”.
Gitte Aabo, CEO and President of LEO Pharma, said: “We are proud to join forces with Almirall to address the urgent need for a skin sampling method that is painless, minimally invasive and clinically validated. Our unique collaboration has the potential to help patients and indeed the entire scientific community in dermatology as we work towards a common goal of advancing understanding of skin diseases”.
The research will be conducted at the Hospital Clinic of Barcelona (Spain), the Technical University of Denmark and the University of Bath (UK). The methodology will be validated in selected patient populations and the final research results will be published in peer reviewed journals.
For more information, please visit almirall.com.
